Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.
Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.
Royalty Pharma plc completed a major debt financing, closing an offering of $600 million 4.450% Senior Notes due 2031, $900 million 5.200% Senior Notes due 2035, and $500 million 5.950% Senior Notes due 2055.
The notes are senior unsecured obligations and are guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. Interest on all three series will be paid semi-annually on March 25 and September 25, beginning March 25, 2026, with final maturities matching each series’ stated due date.
The indenture includes customary covenants and requires Royalty Pharma to offer to repurchase the notes upon certain change of control events. The company also entered into an underwriting agreement with a syndicate of major investment banks that sets the terms and conditions for the sale of these notes.
Royalty Pharma plc is reported in this Schedule 13G/A as having certain Class A ordinary shares beneficially owned by General Atlantic and affiliated funds. Collectively, the Reporting Persons hold an indirect interest in 14,243,870 Class A ordinary shares (issuable upon conversion of Class B interests), representing approximately 3.2% of the Class A ordinary shares outstanding based on an aggregate count of 446,536,920 shares.
The schedule shows the Reporting Persons have 0 sole voting and dispositive power and 14,243,870 shares of shared voting and dispositive power, reflecting that the positions are held through General Atlantic (RP) Collections, LLC and multiple General Atlantic investment funds and entities organized in Delaware, Bermuda and Luxembourg. The General Atlantic entities state they constitute a group under Rule 13d-5 and disclose the conversion feature that creates equivalent Class A exposure. The filing does not report ownership above the 5% threshold.
Royalty Pharma plc reported that Henry Fernandez has stepped down as a member of the Board and as the Board's Lead Independent Director, effective August 13, 2025. The filing states his decision did not result from any disagreement with the company and notes his five years of service and the Board's gratitude for his contributions.
The company disclosed that it issued a press release announcing the departure, which is filed as Exhibit 99.1 and is incorporated by reference. No successor or additional governance changes are described in the filing.
Capital International Investors reports beneficial ownership of 23,111,998 shares of Royalty Pharma plc, representing 5.5% of the approximately 421,370,657 shares believed outstanding. CII is deemed the beneficial owner through its investment management entities and holds sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares. The filing is a Schedule 13G and the reporting person is classified as an investment adviser (IA). The statement certifies the position is held in the ordinary course of business and was not acquired to change or influence control of the issuer.
Gregory Norden, a director of Royalty Pharma plc (RPRX), reported a non-cash exchange and a subsequent sale of Class A ordinary shares on Form 4. On 08/08/2025 he received 144,660 Class A shares in exchange for limited partnership interests in RPI US Partners 2019, LP under an Amended and Restated Exchange Agreement, increasing his reported direct holdings to 228,348 shares prior to any sale. On 08/11/2025 he sold 33,500 shares at a weighted average price of $36.2313 per share (reported range $36.10–$36.40), reducing his direct ownership to 194,848 shares. The Form 4 was signed by an attorney-in-fact.
Royalty Pharma plc submitted a Form 144 proposing the sale of 33,500 Class A ordinary shares through Merrill Lynch on NASDAQ, with an approximate sale date of 08/11/2025. The filing lists an aggregate market value of $1,213,747.00 and 432,293,050 shares outstanding, so the proposed block represents a very small fraction of the company.
The shares were acquired on 04/13/2015 in an exchange of limited partnership interests from Royalty Pharma plc, with cash payment recorded. The filer reports no securities sold in the past three months and includes the standard representation that no material nonpublic information is known.
Pablo G. Legorreta, CEO and Chairman of Royalty Pharma plc, filed a Form 4 reporting an exempt acquisition on 08/06/2025 of 21,901 Class A Ordinary Shares at $0 in connection with settlement of Equity Performance Awards pursuant to Rule 16b-3. The transaction is recorded as an exempt award settlement and increases the reporting persons direct holdings.
The filing itemizes extensive indirect beneficial ownership through entities, trusts and family members with specific share counts such as Legorreta Investments LLC: 460,139, Legorreta Children 2002 Trust: 1,040,410, GST-Exempt Legorreta 2012 Family Trust: 901,590 and Legorreta 2023 SR Trust: 600,000, among others.
The form also discloses LP interests in RPI US Partners 2019, LP that are exchangeable under the Amended and Restated Exchange Agreement into Class A Ordinary Shares for no additional value; entries include a reported change dated 08/08/2025 listing 60,000 LP interests (noted as representing 600,000 Class A Ordinary Shares) and larger RPI US LP interest amounts shown for related entities.
Terrance P. Coyne, EVP & CFO of Royalty Pharma plc (RPRX), reported an exempt acquisition on 08/06/2025 of 3,696 Class A Ordinary Shares in connection with the settlement of Equity Performance Awards. The filing shows the award settlement with a $0 price and cites the acquisition as exempt under Rule 16b-3.
The Form 4 shows the reporting person beneficially owned 52,342 Class A Ordinary Shares following the reported transaction, held indirectly through TPC RP EPA1 LLC. The filing also discloses additional indirect holdings including 790,000 shares held by TPC RP 2021, LLC, IRA and spouse accounts, and a reported disposal of 1,500 shares. The form was signed by attorney-in-fact on 08/08/2025.
Royalty Pharma's Form 4 reports that the reporting person listed as "Lloyd George W." (identified as EVP, Investments & CLO) acquired 3,696 Class A Ordinary Shares on 08/06/2025 through the settlement of Equity Performance Awards, an exempt acquisition pursuant to Rule 16b-3. The filing also records a disposition of 3,000 Class A shares and shows multiple indirect holdings held by several related entities and the reporting person's spouse.
Table II discloses limited partnership interests in RPI US Partners 2019, LP that are exchangeable: each RPI US LP Interest may be exchanged for ten Class B Interests, and each Class B Interest will be exchanged for one Class A Ordinary Share, meaning each LP interest converts into ten Class A shares. The filing lists underlying Class A equivalents of 581,730, 2,917,390, 2,726,720, 1,301,480 and 85,000 related to those interests. The form was signed by an attorney-in-fact on 08/08/2025.
Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc (RPRX), reported insider transactions on Form 4. The filing records an exempt acquisition of 3,696 Class A ordinary shares on 08/06/2025 in connection with the settlement of Equity Performance Awards under Rule 16b-3, recorded with a price of $0. The form also shows a reported disposition of 70,000 Class A ordinary shares (marked as a sale).
After the reported activity, the total beneficial ownership is reported as 652,342 shares, held indirectly through SCH Investment Partners LLC. The filing was signed by an attorney-in-fact on behalf of Mr. Hite.